• Over 12,200 fully anonymized subject records
• Placebo and treatment-arm data from 30 Phase II/III clinical trials
• Demographic, lab, medical and family history, and other data elements
• More than 16 million longitudinally collected data points

The popularity of the project is illustrated by the following statistics:

• Registed users: 2868
• Countries: 85
• Downloads: 19613

We thank everyone who has contributed to the creation of PRO-ACT including the companies, the researchers, and most of all the ALS patients, past and present, around the world, to whom the PRO-ACT initiative is dedicated:

• ALS Therapy Alliance
• Amylyx Pharmaceuticals, Inc.
• Cytokinetics, Inc.
• Knopp Biosciences
• Neuraltus Pharmaceuticals, Inc.
• Neurological Clinical Research Institute, Massachusetts General Hospital
• Northeast ALS Consortium
• Novartis
• Orion Corporation
• Prize4Life Israel
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Teva Pharmaceutical Industries, Ltd.
• The ALS Association